These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Should hospitals report to the FDA? McNaughton DJ Healthc Comput Commun; 1987 Oct; 4(10):29. PubMed ID: 10288562 [No Abstract] [Full Text] [Related]
5. Monitoring of drugs after marketing. J R Coll Gen Pract; 1983 Jul; 33(252):438-41. PubMed ID: 6887114 [No Abstract] [Full Text] [Related]
6. Looking for trouble in medical devices. Stearman DW FDA Consum; 1987 Sep; 21(7):18-23. PubMed ID: 10312181 [No Abstract] [Full Text] [Related]
7. A "complaint department" for medical devices. Thompson RC FDA Consum; 1987 Mar; 21(2):10-3. PubMed ID: 10312180 [No Abstract] [Full Text] [Related]
8. Postmarketing surveillance: statistics and augury. Johnson AF J Chronic Dis; 1984; 37(12):949-52. PubMed ID: 6396318 [No Abstract] [Full Text] [Related]
9. FDA asks LyphoMed to recall intravenous solution. Wagner M Mod Healthc; 1988 Jul; 18(31):5. PubMed ID: 10288204 [No Abstract] [Full Text] [Related]
10. What you should know about FDA-USP Drug Product Problem Reporting Program. McGinnis DM Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472 [No Abstract] [Full Text] [Related]
11. Drug safety and drug efficacy: two sides of the same coin. Young RC; Friedman MA; Schilsky RL; Sigal EV Clin Cancer Res; 2007 May; 13(9):2533-4. PubMed ID: 17473179 [No Abstract] [Full Text] [Related]
12. Policy issues concerning antimicrobials: problems with the regulatory process governing their introduction. Simon HJ Hosp Formul; 1985 May; 20(5):629-31, 634. PubMed ID: 10271104 [TBL] [Abstract][Full Text] [Related]
13. Adverse-drug-reaction monitoring. Faich GA N Engl J Med; 1986 Jun; 314(24):1589-92. PubMed ID: 3713757 [No Abstract] [Full Text] [Related]
14. FDA evaluation of antimicrobials: subgroup analysis. Powers JH; Lin D; Ross D Chest; 2005 Jun; 127(6):2298-9; authore reply 2300-1. PubMed ID: 15947370 [No Abstract] [Full Text] [Related]
15. Adverse drug reaction reporting. Bosco LA Am J Gastroenterol; 1987 Apr; 82(4):356-7. PubMed ID: 3565343 [No Abstract] [Full Text] [Related]
16. Report device failures to the FDA. JCAH Perspect; 1987; 7(7-8):5-7. PubMed ID: 10289785 [No Abstract] [Full Text] [Related]
17. Not enough warning. GAO report finds FDA's medical device monitoring lacking. Hensley S Mod Healthc; 1997 Mar; 27(10):102, 104. PubMed ID: 10165267 [No Abstract] [Full Text] [Related]
18. The Food and Drug Administration Amendments Act and postmarketing commitments. Fain K; Daubresse M; Alexander GC JAMA; 2013 Jul; 310(2):202-4. PubMed ID: 23839755 [No Abstract] [Full Text] [Related]
19. Adverse drug event reporting. Improving the low US reporting rates. Edlavitch SA Arch Intern Med; 1988 Jul; 148(7):1499-503. PubMed ID: 3382293 [No Abstract] [Full Text] [Related]
20. Post-marketing surveillance, annual reports and long term follow-up. Jones JK Drug Inf J; 1982; 16(1-2):87-92. PubMed ID: 10317304 [No Abstract] [Full Text] [Related] [Next] [New Search]